Key result
Continuous-flow left ventricular assist device support did not statistically improve peak oxygen consumption at any time point after implantation compared to baseline (11.2 ml/kg/min).
Why the study?
Does continuous-flow left ventricular assist device (cfLVAD) support improve exercise capacity as measured by peak VO2 in patients with advanced heart failure?
Observational
Does continuous-flow left ventricular assist device (cfLVAD) support improve exercise capacity as measured by peak VO2 in patients with advanced heart failure?
Exercise capacity measured by peak VO2 does not significantly improve after cfLVAD implantation in patients with advanced heart failure, despite known survival and quality of life benefits.
cfLVAD support may not improve peak VO2 despite survival benefits; leaves open mechanisms limiting exercise capacity gains in advanced HF.
Continuous-flow left ventricular assist devices (cfLVADs) have been proven safe and effective for bridge-to-transplant and destination therapy (DT) in patients with advanced heart failure. However, the fixed pump speed of these devices may lack response to activity and oxygen demand, thereby limiting exercise tolerance. The objective of this observational study was to describe exercise capacity as measured by peak oxygen consumption (peak VO2) that may be expected during support with a cfLVAD. Peak VO2 was measured in patients (mean age: 58.3 ± 11.7 years; 66.7% ischemic and 33.3% DT) before cfLVAD support (11.2 ± 3.0 ml/kg/min, n = 25), between 3 and 6 months (12.7 ± 3.5 ml/kg/min, n = 31), at 1 year (10.7 ± 2.6 ml/kg/min, n = 16), and longer than 1 year (11.2 ± 1.7 ml/kg/min, n = 10). There was no statistical improvement in peak VO2 at any time point after implantation. In addition, ventilatory efficiency remained poor after LVAD implantation at all time points. Although studies have shown an increase in survival and patient's quality of life, exercise capacity as measured by cardiopulmonary exercise testing remains low during cfLVAD support.
No takes yet. Share an insight, caveat, or question.
Leibner et al. (2013) conducted an observational in advanced heart failure. Continuous-flow left ventricular assist devices (cfLVADs) vs. Before cfLVAD support (baseline) was evaluated on exercise capacity as measured by peak oxygen consumption (peak VO2). Continuous-flow left ventricular assist device support did not statistically improve peak oxygen consumption at any time point after implantation compared to baseline (11.2 ml/kg/min).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: